AdvanTIG-105: Phase 1b Dose-Expansion Study of Ociperlimab plus Tislelizumab in Patients with Metastatic NSCLC

被引：0
|
作者：
Kumar, R. [1 ,2 ]
Kim, S. H. [3 ]
Zhong, D. [4 ]
Lu, S. [5 ]
Cheng, Y. [6 ]
Chen, M. [7 ]
Cho, E. [8 ]
Clay, T. [9 ]
Kang, J. -H. [10 ]
Lee, G. -W. [11 ]
Sun, M. [12 ]
Shim, B. -Y. [13 ]
Spigel, D. R. [14 ]
Yang, T. -Y. [15 ]
Wang, Q. [16 ]
Chang, G. -C. [17 ]
Yu, G. [18 ]
Wang, R. [19 ]
Luo, X. [19 ]
Zheng, H. [20 ]
Gao, R. [19 ]
Kim, H. R. [21 ]
机构：
[1] New Zealand Clin Res, Christchurch, New Zealand
[2] Univ Otago, Dept Pathol, Dunedin, New Zealand
[3] Seoul Natl Univ, Coll Med, Bundang Hosp, Dept Internal Med,Div Hematol & Med Oncol, Seongnam, South Korea
[4] Tianjin Med Univ, Dept Oncol, Gen Hosp, Tianjin, Peoples R China
[5] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai, Peoples R China
[6] Jilin Canc Hosp, Dept Thorac Oncol, Changchun, Peoples R China
[7] Zhejiang Univ Canc Hosp, Dept Bioinformat, Coll Life Sci, State Key Lab Plant Physiol & Biochem, Hangzhou, Peoples R China
[8] Gachon Univ, Coll Med, Gil Med Ctr, Incheon, South Korea
[9] St John God Subaico Hosp, Dept Med Oncol, Subiaco, WA, Australia
[10] Catholic Univ Korea, Seoul St Marys Hosp, Div Med Oncol, Dept Internal Med,Coll Med, Seoul, South Korea
[11] Gyeongsang Natl Univ, Coll Med, Gyeongsang Natl Univ Hosp, Div Hematol & Oncol,Dept Internal Med, Jinju, South Korea
[12] Shandong First Med Univ, Shandong Univ, Jinan Cent Hosp, Dept Oncol, Jinan, Peoples R China
[13] Catholic Univ Korea, Dept Med Oncol, St Vincents Hosp, Dept Internal Med, Suwon, South Korea
[14] Sarah Cannon Res Inst SCRI, Tennessee Oncol, PLLC, Nashville, TN USA
[15] Taichung Vet Gen Hosp, Dept Internal Med, Div Chest Med, Taichung, Taiwan
[16] Zhengzhou Univ, Henan Canc Hosp, Dept Internal Med, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[17] Chung Shan Med Univ Hosp, Div Pulm Med, Dept Internal Med, Taichung, Taiwan
[18] Weifang Med Univ, Weifang Peoples Hosp, Oncol Dept, Weifang, Peoples R China
[19] BeiGene Shanghai Co Ltd, Shanghai, Peoples R China
[20] BeiGene USA Inc, San Mateo, CA USA
[21] Yonsei Univ, Dept Internal Med, Yonsei Canc Ctr, Coll Med,Div Med Oncol, Seoul, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
TIGIT antibody; PD-1; inhibitor; metastatic NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.01-07
引用
收藏
页码：S375 / S376
页数：2
相关论文
共 50 条
  • [21] AdvanTIG-205: Phase II trial of ociperlimab (OCI) plus tislelizumab (TIS) plus chemotherapy (chemo) in first line (1L) treatment of patients (pts) with locally advanced (LA), unresectable, or metastatic non-small cell lung cancer (mNSCLC)
    Zhu, B.
    Kim, T. M.
    Patel, S. A.
    Parakh, S.
    Tang, J.
    Wu, H.
    Girard, N.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1094 - S1094
  • [22] AdvanTIG-202: Phase II randomized, multicenter, open-label study of tislelizumab (TIS) with or without ociperlimab (OCI) in patients (pts) with previously treated recurrent/metastatic (R/M) cervical cancer (CC)
    Lee, J-Y.
    Wu, L.
    Boonyapipat, S.
    Kim, H. S.
    Lee, J-W.
    Wang, L.
    Wang, T.
    Wang, D.
    Yao, D.
    Liu, H.
    Andabekov, T.
    Zhang, X.
    Wang, W.
    Kim, Y. M.
    Wang, K.
    Gao, Y.
    Mu, X.
    Sinielnikov, I. Volodymyrovych
    ANNALS OF ONCOLOGY, 2023, 34 : S509 - S510
  • [23] A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC
    Camidge, D. Ross
    Barlesi, Fabrice
    Goldman, Jonathan W.
    Morgensztern, Daniel
    Heist, Rebecca
    Vokes, Everett
    Angevin, Eric
    Hong, David S.
    Rybkin, Igor I.
    Barve, Minal
    Bauer, Todd M.
    Delmonte, Angelo
    Dunbar, Martin
    Motwani, Monica
    Parikh, Apurvasena
    Noon, Elysa
    Wu, Jun
    Blot, Vincent
    Kelly, Karen
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (01):
  • [24] Phase 1b study of aldoxorubicin plus gemcitabine in metastatic solid tumors.
    Sankhala, Kamalesh Kumar
    Chawla, Shanta
    Chua, Victoria S.
    Sachdev, Jasgit C.
    Borazanci, Erkut Hasan
    Sung, Kelli
    Mita, Monica M.
    Mita, Alain C.
    Laabs, Brenda
    Wieland, Scott
    Levitt, Daniell.
    Chawla, Sant P.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [25] Sitravatinib plus tislelizumab in patients with anti-PD-(L)1 refractory/resistant metastatic NSCLC
    Gao, B.
    Ma, Z.
    Yu, X.
    Huang, D.
    Zhao, J.
    Day, D.
    Body, A. L.
    Zhou, Q.
    Chu, Q.
    Pan, H.
    Cui, J.
    Chen, C.
    Xiang, X.
    Fei, C.
    Yang, L.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2021, 32 : S998 - S998
  • [26] AdvanTIG-203: A randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab versus tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1)
    Xu, Rui-hua
    Kim, Sung-Bae
    Tougeron, David
    Zuo, Yunxia
    Yang, Haiyuan
    Zhang, Juan
    Shi, Jingwen
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [27] A phase 1b dose-escalation study of TRC105 (endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma (mRCC)
    Choueiri, T.
    Michaelson, M. D.
    Posadas, E.
    Sonpavde, G.
    McDermott, D.
    Seon, B.
    Jivani, M.
    Shazer, R.
    Adams, B.
    Theuer, C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [28] A Phase 1b Dose-Escalation Study of TRC105 in Combination with Nivolumab in Patients with Metastatic Non-Small Cell Lung Cancer
    Robert, F.
    Theuer, C.
    Saleh, M.
    Keef, J.
    Jerome, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1976 - S1976
  • [29] Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1 refractory/resistant unresectable or metastatic melanoma from a phase 1b study.
    Cui, Chuanliang
    Pan, Hongming
    Carlino, Matteo
    Cui, Jiuwei
    Wang, Xuan
    Chen, Cheng
    Xiang, Xiao
    Yang, Liu
    Guo, Jun
    CANCER RESEARCH, 2021, 81 (13)
  • [30] AdvanTIG-203: Phase II randomized, multicenter study of ociperlimab (OCI) plus tislelizumab (TIS) in patients (pts) with unresectable, locally advanced, recurrent/metastatic esophageal squamous cell carcinoma (ESCC) and programmed cell death-ligand 1 (PD-L1) positivity
    Wang, F.
    Lin, C-Y.
    Sun, J-M.
    Lu, C-H.
    Zhu, X.
    Chen, Z.
    Kim, I-H.
    Pan, Y.
    Zhang, J.
    Chen, Z.
    Tougeron, D.
    Kim, S-B.
    Van Cutsem, E.
    Abdrashitov, R.
    Ge, R.
    Sun, J.
    Zhou, J.
    Xu, R-H.
    ANNALS OF ONCOLOGY, 2023, 34 : S621 - S621
12345